Seagen and astellas announce positive topline results for padcev® (enfortumab vedotin-ejfv) with keytruda® (pembrolizumab) as first-line treatment for advanced urothelial cancer

Bothell, wash. & tokyo--(business wire)--seagen inc. (nasdaq:sgen) and astellas pharma inc. (tse:4503, president and ceo: kenji yasukawa, ph.d., “astellas”) today announced positive topline results from the phase 1b/2 ev-103 clinical trial (also known as keynote-869) cohort k evaluating padcev® (enfortumab vedotin-ejfv) in combination with merck's anti-pd-1 therapy keytruda® (pembrolizumab) as first-line treatment in patients with unresectable locally advanced or metastatic urothelial cancer (l
SGEN Ratings Summary
SGEN Quant Ranking